Deutsch Intern
    Rudolf Virchow Center for Integrative and Translational Bioimaging

    Tracking down cryptic peptides


    Using a newly developed method, researchers from the University of Würzburg, in cooperation with the University Hospital of Würzburg, were able to identify thousands of special peptides on the surface of cells for the first time. They were able to show that these so-called cryptic peptides mark a significant proportion of tumor cells. These findings could provide a new starting point for cancer immunotherapy and were published in the renowned journal Cancer Immunology Research.

    [Translate to Englisch:] Abbildung 1: Schematische Darstellung der Entstehung und Präsentation von kryptischen Peptiden (Bild: AG Schlosser)

    Almost all cells of the human body present fragments of cellular proteins on their surface, so-called human leukocyte antigens or HLA peptides, which play an important role in the immune response. If the immune system detects foreign HLA peptides, such as viral peptides on a virus-infected cell or mutated peptides on a tumour cell, T-cells eliminate the corresponding cell. The entirety of the HLA peptides presented on a cell is referred to as the cell´s immunopeptidome.

    New approach enables comprehensive analysis for the first time

    Besides the usual HLA peptides, there are also cryptic HLA peptides. These are derived from specific RNA sequences that do not contain information for a specific protein as is usually the case. Over the last few decades, only a few cryptic HLA peptides have been identified because they are very small and are quickly degraded in the cells. On the other hand, efficient computer algorithms for the analysis were lacking.
    In a completely new approach, the Würzburg scientists have now combined several analytical methods that are particularly suitable for small peptides. "Using a novel bioinformatics method developed by us, for the first time we were able to identify thousands of cryptic HLA peptides in the immunopeptidomes of a wide variety of tumors such as melanoma and breast cancer," explains Dr. Andreas Schlosser, research group leader at the Rudolf Virchow Center at the University of Würzburg.
    The new bioinformatics approach is based exclusively on data from mass spectrometry, a method for determining the mass of molecules such as Peptides. This makes it possible to systematically and comprehensively determine the cryptic HLA peptides. In addition, it was possible to clarify on which cells and to what extent cryptic peptides are present: "We were able to show that cryptic HLA peptides make up a significant part of the immunopeptidomes of tumors," explains Prof. Dr. Florian Erhard, group leader at the Institute of Virology at the University of Würzburg.

    Effective points of attack for the immune system

    It was already known from individual studies that cryptic peptides can trigger autoimmune reactions such as in diabetes type 1 as well as immune responses against tumor cells. The new analyses provide evidence that certain cryptic HLA peptides are exclusively found on tumour cells. Such tumour-specific cryptic HLA peptides might thus prove to be worthwhile target structures for cancer immunotherapies. Scientists at the University of Würzburg and the University Hospital of Würzburg are already examining a selection of the identified peptides to determine whether they are suitable as targets for cancer immunotherapy.
    Virus-infected cells also present cryptic HLA peptides that could be used as a target structure for vaccines. With their new method, the researchers thus have an effective tool in hand to learn more about the general function and formation of cryptic peptides. "We hope that our bioinformatics approach will provide us with a better understanding of autoimmune reactions as well as immune reactions against tumour cells and virus-infected cells," says Schlosser.



    Florian Erhard, Lars Dölken, Bastian Schilling, Andreas Schlosser: Identification of the cryptic HLA-I immunopeptidome Cancer Immunology Research (Juni 2020) doi: 10.1158/2326-6066.CIR-19-0886.


    Prof. Dr. Florian Erhard is head of a research group at the Institute of Virology and Immunobiology at the University of Würzburg.

    Dr. Andreas Schlosser is head of a research group at the Rudolf Virchow Center for Integrative and Translational Bioimaging at the University of Würzburg.


    Dr. Andreas Schlosser (AG Schlosser, Rudolf Virchow Center at University of Würzburg)
    Tel: +49 931 31-86888, andreas.schlosser@virchow.uni-wuerzburg.de


    Dr. Judith Flurer (Press Office, Rudolf Virchow Center)
    Tel.: +49 931 31-85822, judith.flurer@uni-wuerzburg.de